Contact this trialFirst, we need to learn more about you.
Hormone Therapy
Galunisertib + Enzalutamide for Prostate Cancer
Recruiting1 awardPhase 2
Washington, District of Columbia
This trial is testing if adding LY2157299 to enzalutamide helps people with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.